Information on National Health Service expenditure on drugs for the treatment of asthma in primary and secondary care is in the table.<\/p>
<\/p>
<\/strong><\/p> <\/p> Drugs for the treatment of osteoporosis have been defined as those included in the following British National Formulary sections:<\/p> <\/p> 3.1.1 Adrenoceptor agonists<\/p> <\/p> 3.1.2 Antimuscarinic bronchodilators<\/p> <\/p> 3.1.3 Theophylline<\/p> <\/p> 3.2 Corticosteroids<\/p> <\/p> 3.3.1 Cromoglicate and related therapy<\/p> <\/p> 3.3.2 Leukotriene receptor antagonists<\/p> <\/p> 3.4.2 Allergen immunotherapy (omalizumab only)<\/p> <\/p> <\/p> <\/p> Cost of drugs for the treatment of asthma, England1<\/sup><\/p><\/td><\/tr> Drug name<\/p><\/td> Primary Care (£ millions)<\/p><\/td> Secondary Care (£ millions)<\/p><\/td><\/tr> 2009<\/p><\/td> 2010<\/p><\/td> 2011<\/p><\/td> 2012<\/p><\/td> 2013<\/p><\/td> 2009<\/p><\/td> 2010<\/p><\/td> 2011<\/p><\/td> 2012<\/p><\/td> 2013<\/p><\/td><\/tr> Aclidinium Bromide<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.02<\/p><\/td> 1.62<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.00<\/p><\/td> 0.03<\/p><\/td><\/tr> Aminophylline<\/p><\/td> 1.25<\/p><\/td> 1.18<\/p><\/td> 1.12<\/p><\/td> 1.08<\/p><\/td> 1.05<\/p><\/td> 0.30<\/p><\/td> 0.29<\/p><\/td> 0.21<\/p><\/td> 0.23<\/p><\/td> 0.22<\/p><\/td><\/tr> Beclometasone Dipropionate<\/p><\/td> 84.26<\/p><\/td> 87.72<\/p><\/td> 90.30<\/p><\/td> 97.56<\/p><\/td> 102.39<\/p><\/td> 1.62<\/p><\/td> 1.53<\/p><\/td> 1.41<\/p><\/td> 1.49<\/p><\/td> 1.42<\/p><\/td><\/tr> Budesonide<\/p><\/td> 140.35<\/p><\/td> 149.03<\/p><\/td> 158.82<\/p><\/td> 169.14<\/p><\/td> 177.00<\/p><\/td> 1.29<\/p><\/td> 1.14<\/p><\/td> 1.14<\/p><\/td> 1.27<\/p><\/td> 1.41<\/p><\/td><\/tr> Budesonide/ Formoterol<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 2.75<\/p><\/td> 2.94<\/p><\/td> 2.89<\/p><\/td> 3.10<\/p><\/td> 3.29<\/p><\/td><\/tr> Ciclesonide<\/p><\/td> 0.84<\/p><\/td> 0.95<\/p><\/td> 1.03<\/p><\/td> 1.12<\/p><\/td> 1.25<\/p><\/td> 0.01<\/p><\/td> 0.02<\/p><\/td> 0.02<\/p><\/td> 0.02<\/p><\/td> 0.03<\/p><\/td><\/tr> Fluticasone<\/p><\/td> 366.24<\/p><\/td> 380.56<\/p><\/td> 387.89<\/p><\/td> 392.95<\/p><\/td> 396.10<\/p><\/td> 1.00<\/p><\/td> 0.93<\/p><\/td> 0.91<\/p><\/td> 1.00<\/p><\/td> 0.99<\/p><\/td><\/tr> Fluticasone/ Salmeterol<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 11.46<\/p><\/td> 11.56<\/p><\/td> 10.69<\/p><\/td> 10.82<\/p><\/td> 10.48<\/p><\/td><\/tr> Formoterol Fumarate<\/p><\/td> 5.18<\/p><\/td> 4.87<\/p><\/td> 4.68<\/p><\/td> 4.85<\/p><\/td> 4.93<\/p><\/td> 0.10<\/p><\/td> 0.08<\/p><\/td> 0.07<\/p><\/td> 0.06<\/p><\/td> 0.06<\/p><\/td><\/tr> Glycopyrronium Bromide<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.01<\/p><\/td> 2.30<\/p><\/td> 0.58<\/p><\/td> 0.62<\/p><\/td> 0.70<\/p><\/td> 0.79<\/p><\/td> 1.00<\/p><\/td><\/tr> Indacaterol Maleate<\/p><\/td> -<\/p><\/td> 0.04<\/p><\/td> 0.30<\/p><\/td> 0.92<\/p><\/td> 1.47<\/p><\/td> -<\/p><\/td> 0.00<\/p><\/td> 0.00<\/p><\/td> 0.02<\/p><\/td> 0.04<\/p><\/td><\/tr> Ipratropium Bromide<\/p><\/td> 16.15<\/p><\/td> 15.02<\/p><\/td> 13.74<\/p><\/td> 10.32<\/p><\/td> 8.61<\/p><\/td> 2.74<\/p><\/td> 2.84<\/p><\/td> 2.59<\/p><\/td> 2.65<\/p><\/td> 2.70<\/p><\/td><\/tr> Mometasone Furoate<\/p><\/td> 0.36<\/p><\/td> 0.31<\/p><\/td> 0.26<\/p><\/td> 0.23<\/p><\/td> 0.21<\/p><\/td> 0.76<\/p><\/td> 0.71<\/p><\/td> 0.61<\/p><\/td> 0.63<\/p><\/td> 0.67<\/p><\/td><\/tr> Montelukast<\/p><\/td> 38.91<\/p><\/td> 43.01<\/p><\/td> 46.96<\/p><\/td> 51.71<\/p><\/td> 31.31<\/p><\/td> 0.98<\/p><\/td> 1.02<\/p><\/td> 1.03<\/p><\/td> 1.16<\/p><\/td> 0.81<\/p><\/td><\/tr> Omalizumab<\/p><\/td> 0.00<\/p><\/td> 0.01<\/p><\/td> 0.03<\/p><\/td> 0.15<\/p><\/td> 0.12<\/p><\/td> 5.97<\/p><\/td> 9.22<\/p><\/td> 12.16<\/p><\/td> 14.65<\/p><\/td> 17.86<\/p><\/td><\/tr> Salbutamol<\/p><\/td> 83.15<\/p><\/td> 82.64<\/p><\/td> 60.58<\/p><\/td> 60.37<\/p><\/td> 59.95<\/p><\/td> 3.78<\/p><\/td> 3.77<\/p><\/td> 3.36<\/p><\/td> 3.38<\/p><\/td> 3.29<\/p><\/td><\/tr> Salmeterol<\/p><\/td> 48.80<\/p><\/td> 45.16<\/p><\/td> 41.87<\/p><\/td> 36.72<\/p><\/td> 34.04<\/p><\/td> 0.87<\/p><\/td> 0.74<\/p><\/td> 0.59<\/p><\/td> 0.53<\/p><\/td> 0.47<\/p><\/td><\/tr> Terbutaline Sulphate<\/p><\/td> 8.61<\/p><\/td> 8.20<\/p><\/td> 7.61<\/p><\/td> 7.43<\/p><\/td> 7.18<\/p><\/td> 0.18<\/p><\/td> 0.16<\/p><\/td> 0.14<\/p><\/td> 0.14<\/p><\/td> 0.15<\/p><\/td><\/tr> Theophylline<\/p><\/td> 2.18<\/p><\/td> 2.17<\/p><\/td> 2.15<\/p><\/td> 2.22<\/p><\/td> 2.26<\/p><\/td> 0.12<\/p><\/td> 0.11<\/p><\/td> 0.11<\/p><\/td> 0.11<\/p><\/td> 0.11<\/p><\/td><\/tr> Tiotropium<\/p><\/td> 113.61<\/p><\/td> 129.98<\/p><\/td> 149.81<\/p><\/td> 169.35<\/p><\/td> 185.24<\/p><\/td> 5.69<\/p><\/td> 6.03<\/p><\/td> 6.22<\/p><\/td> 6.64<\/p><\/td> 6.87<\/p><\/td><\/tr> Zafirlukast<\/p><\/td> 0.79<\/p><\/td> 0.71<\/p><\/td> 0.71<\/p><\/td> 0.70<\/p><\/td> 0.69<\/p><\/td> 0.01<\/p><\/td> 0.01<\/p><\/td> 0.01<\/p><\/td> 0.01<\/p><\/td> 0.01<\/p><\/td><\/tr> Other drugs2<\/sup><\/p><\/td> 0.90<\/p><\/td> 0.79<\/p><\/td> 0.66<\/p><\/td> 0.62<\/p><\/td> 0.60<\/p><\/td> 0.04<\/p><\/td> 0.07<\/p><\/td> 0.15<\/p><\/td> 0.26<\/p><\/td> 0.46<\/p><\/td><\/tr> Total<\/p><\/td> 911.6<\/p><\/td> 952.3<\/p><\/td> 968.5<\/p><\/td> 1,007.5<\/p><\/td> 1,018.3<\/p><\/td> 40.3<\/p><\/td> 43.8<\/p><\/td> 45.0<\/p><\/td> 49.0<\/p><\/td> 52.4<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> 1 <\/sup>Cost of drugs at NHS list price not taking account of discounts, dispensing costs, fees or prescription charges income. Totals may not add up due to rounding.<\/p> <\/p> 2<\/sup> Other drugs include Azelastine/Fluticasone, Bambuterol Hydrochloride, Beclometasone/ Formoterol, Cromoglicic Acid, Fenoterol Hydrobromide, Fenoterol/Ipratropium Bromide, Fluticasone/ Formoterol, Nedocromil Sodium, Orciprenaline Sulfate and Sodium Cromoglicate.<\/p> <\/p> Source:<\/p> <\/p> Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care)<\/p> <\/p> Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care)<\/p> <\/p> <\/p> <\/p> Since some drugs are prescribed to treat more than one condition and as the condition for which a drug is prescribed is not collected, it is not possible to separate the different conditions for which a drug may have been prescribed. The information provided may therefore include costs from the prescribing of these drugs for conditions other than for asthma.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-10-29T17:13:01.0657405Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much has been spent on the prescription of asthma drugs in the NHS in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester West"}
, "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
], "uin" : "211846"}
, {"_about" : "http://data.parliament.uk/resources/100885", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/100885/answer", "answerText" : {"_value" : " The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p> <\/p> <\/p> <\/p> £ million<\/em><\/p> <\/p> 2009-10<\/p><\/td> 2010-11<\/p><\/td> 2011-12<\/p><\/td> 2012-13<\/p><\/td> 2013-14<\/p><\/td><\/tr> Asthma<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> Other Research Councils and Innovate UK<\/p><\/td> 0.0<\/p><\/td> 0.1<\/p><\/td> 0.3<\/p><\/td> 1.5<\/p><\/td> 0.8<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 2.6<\/p><\/td> 3.4<\/p><\/td> 2.4<\/p><\/td> 3.4<\/p><\/td> 3.8<\/p><\/td><\/tr> Total<\/p><\/td> Motor Neurone Research<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> 7.0<\/p><\/td> 7.5<\/p><\/td> 4.2<\/p><\/td> 4.1<\/p><\/td> 3.6<\/p><\/td><\/tr> Other Research Councils and Innovate UK<\/p><\/td> 0.2<\/p><\/td> 0.2<\/p><\/td> 0.4<\/p><\/td> 0.7<\/p><\/td> 1.0<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.4<\/p><\/td> 0.7<\/p><\/td> 0.5<\/p><\/td><\/tr> Total<\/p><\/td> 7.3<\/p><\/td> 7.8<\/p><\/td> 5.0<\/p><\/td> 5.5<\/p><\/td> 5.1<\/p><\/td><\/tr> Osteoporosis<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> 6.2<\/p><\/td> 5.4<\/p><\/td> 5.1<\/p><\/td> 4.6<\/p><\/td> 5.9<\/p><\/td><\/tr> Other Research Councils and Innovate UK<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.1<\/p><\/td> 0.4<\/p><\/td> 1.0<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 0.3<\/p><\/td> 0.7<\/p><\/td> 0.8<\/p><\/td> 1.3<\/p><\/td> 1.8<\/p><\/td><\/tr> Total<\/p><\/td> 6.5<\/p><\/td> 6.1<\/p><\/td> 6.0<\/p><\/td> 6.3<\/p><\/td> 8.7<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p> <\/p> <\/p> <\/p> Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p> <\/p> <\/p> <\/p> Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100885/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
}
, "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:29.113Z", "_datatype" : "dateTime"}
], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much the Government has spent on the development of new drugs to treat the symptoms of asthma in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester West"}
, "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
], "uin" : "211885"}
, {"_about" : "http://data.parliament.uk/resources/100886", "AnsweringBody" : [{"_value" : "Cabinet Office"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/100886/answer", "answerText" : {"_value" : " The information requested falls within the responsibility of the UK Statistics Authority. I have asked the Authority to reply.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1556", "label" : {"_value" : "Biography information for Mr Rob Wilson"}
}
, "answeringMemberConstituency" : {"_value" : "Reading East"}
, "answeringMemberPrinted" : {"_value" : "Mr Rob Wilson"}
, "attachment" : {"_about" : "http://data.parliament.uk/resources/100886/answer/attachment/1", "fileName" : {"_value" : "PQ 211917 ONS 369.pdf"}
, "title" : "ONS Letter to Member - Death from Asthma"}
, "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-10-29T16:57:49.537Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "53"}
, "answeringDeptShortName" : {"_value" : "Cabinet Office"}
, "answeringDeptSortName" : {"_value" : "Cabinet Office"}
, "date" : {"_value" : "2014-10-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Minister for the Cabinet Office, how many people (a) under and (b) over the age of 18 died as a result of asthma in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester West"}
, "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
], "uin" : "211917"}
, {"_about" : "http://data.parliament.uk/resources/100887", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/100887/answer", "answerText" : {"_value" : " The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p> <\/p> <\/p> <\/p> £ million<\/em><\/p> <\/p> 2009-10<\/p><\/td> 2010-11<\/p><\/td> 2011-12<\/p><\/td> 2012-13<\/p><\/td> 2013-14<\/p><\/td><\/tr> Asthma<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> Other Research Councils and Innovate UK<\/p><\/td> 0.0<\/p><\/td> 0.1<\/p><\/td> 0.3<\/p><\/td> 1.5<\/p><\/td> 0.8<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 2.6<\/p><\/td> 3.4<\/p><\/td> 2.4<\/p><\/td> 3.4<\/p><\/td> 3.8<\/p><\/td><\/tr> Total<\/p><\/td> Motor Neurone Research<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> 7.0<\/p><\/td> 7.5<\/p><\/td> 4.2<\/p><\/td> 4.1<\/p><\/td> 3.6<\/p><\/td><\/tr> Other Research Councils and Innovate UK<\/p><\/td> 0.2<\/p><\/td> 0.2<\/p><\/td> 0.4<\/p><\/td> 0.7<\/p><\/td> 1.0<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.4<\/p><\/td> 0.7<\/p><\/td> 0.5<\/p><\/td><\/tr> Total<\/p><\/td> 7.3<\/p><\/td> 7.8<\/p><\/td> 5.0<\/p><\/td> 5.5<\/p><\/td> 5.1<\/p><\/td><\/tr> Osteoporosis<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> 6.2<\/p><\/td> 5.4<\/p><\/td> 5.1<\/p><\/td> 4.6<\/p><\/td> 5.9<\/p><\/td><\/tr> Other Research Councils and Innovate UK<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.1<\/p><\/td> 0.4<\/p><\/td> 1.0<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 0.3<\/p><\/td> 0.7<\/p><\/td> 0.8<\/p><\/td> 1.3<\/p><\/td> 1.8<\/p><\/td><\/tr> Total<\/p><\/td> 6.5<\/p><\/td> 6.1<\/p><\/td> 6.0<\/p><\/td> 6.3<\/p><\/td> 8.7<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p> <\/p> <\/p> <\/p> Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p> <\/p> <\/p> <\/p> Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100887/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
}
, "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"}
], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much public funding was allocated to research into asthma in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester West"}
, "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
], "uin" : "211918"}
, {"_about" : "http://data.parliament.uk/resources/100720", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/100720/answer", "answerText" : {"_value" : " Information on National Health Service expenditure on drugs for the treatment of osteoporosis in primary and secondary care is in the table.<\/p> <\/p> <\/p> <\/p> Drugs for the treatment of osteoporosis have been defined as those included in the following British National Formulary sections:<\/p> <\/p> 6.6 Drugs affecting bone metabolism<\/p> <\/p> 9.5.1.1 Calcium supplements<\/p> <\/p> 9.6 Vitamins (colecalciferol and ergocalciferol only)<\/p> <\/p> <\/strong><\/p> <\/p> Cost of drugs for the treatment of osteoporosis, England1<\/sup><\/p><\/td><\/tr> Drug Name2<\/sup><\/p><\/td> Primary Care<\/p> (£ million)<\/p><\/td> Secondary Care<\/p> (£ million)<\/p><\/td><\/tr> Year<\/p><\/td> 2009<\/p><\/td> 2010<\/p><\/td> 2011<\/p><\/td> 2012<\/p><\/td> 2013<\/p><\/td> 2009<\/p><\/td> 2010<\/p><\/td> 2011<\/p><\/td> 2012<\/p><\/td> 2013<\/p><\/td><\/tr> Alendronic Acid<\/p><\/td> 14.0<\/p><\/td> 12.4<\/p><\/td> 10.8<\/p><\/td> 9.7<\/p><\/td> 8.9<\/p><\/td> 0.8<\/p><\/td> 0.6<\/p><\/td> 0.5<\/p><\/td> 0.5<\/p><\/td> 0.4<\/p><\/td><\/tr> Alendronic Acid and Colecalciferol<\/p><\/td> 1.4<\/p><\/td> 1.2<\/p><\/td> 0.9<\/p><\/td> 0.7<\/p><\/td> 0.6<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td><\/tr> Calcitonin (Salmon)<\/p><\/td> 0.3<\/p><\/td> 0.3<\/p><\/td> 0.2<\/p><\/td> 0.2<\/p><\/td> 0.1<\/p><\/td> 0.0<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td><\/tr> Calcium<\/p><\/td> 4.2<\/p><\/td> 4.7<\/p><\/td> 4.5<\/p><\/td> 3.7<\/p><\/td> 3.3<\/p><\/td> 0.9<\/p><\/td> 0.9<\/p><\/td> 0.9<\/p><\/td> 0.9<\/p><\/td> 0.9<\/p><\/td><\/tr> Calcium and Colecalciferol<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 2.2<\/p><\/td> 2.2<\/p><\/td> 2.1<\/p><\/td> 2.2<\/p><\/td> 2.3<\/p><\/td><\/tr> Clodronic Acid<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 2.9<\/p><\/td> 2.4<\/p><\/td> 1.6<\/p><\/td> 1.2<\/p><\/td> 0.9<\/p><\/td><\/tr> Colecalciferol<\/p><\/td> 42.4<\/p><\/td> 48.3<\/p><\/td> 58.5<\/p><\/td> 67.6<\/p><\/td> 75.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.4<\/p><\/td> 1.2<\/p><\/td><\/tr> Denosumab<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.2<\/p><\/td> 0.8<\/p><\/td> 1.9<\/p><\/td> 0.0<\/p><\/td> 0.1<\/p><\/td> 0.9<\/p><\/td> 2.3<\/p><\/td> 9.9<\/p><\/td><\/tr> Disodium Etidronate<\/p><\/td> 1.3<\/p><\/td> 1.0<\/p><\/td> 0.8<\/p><\/td> 0.6<\/p><\/td> 0.3<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td><\/tr> Ergocalciferol<\/p><\/td> 4.3<\/p><\/td> 7.8<\/p><\/td> 8.0<\/p><\/td> 7.0<\/p><\/td> 6.1<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.2<\/p><\/td> 0.3<\/p><\/td><\/tr> Ibandronic Acid<\/p><\/td> 12.1<\/p><\/td> 12.1<\/p><\/td> 11.4<\/p><\/td> 10.6<\/p><\/td> 4.7<\/p><\/td> 2.1<\/p><\/td> 2.0<\/p><\/td> 1.8<\/p><\/td> 1.5<\/p><\/td> 0.9<\/p><\/td><\/tr> Pamidronic Acid<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 9.6<\/p><\/td> 9.1<\/p><\/td> 9.4<\/p><\/td> 9.4<\/p><\/td> 8.7<\/p><\/td><\/tr> Risedronate Sodium and Risedronate Acid<\/p><\/td> 27.9<\/p><\/td> 22.9<\/p><\/td> 11.6<\/p><\/td> 2.4<\/p><\/td> 2.0<\/p><\/td> 0.8<\/p><\/td> 0.6<\/p><\/td> 0.3<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td><\/tr> Sodium Clodronate<\/p><\/td> 7.8<\/p><\/td> 7.2<\/p><\/td> 6.3<\/p><\/td> 5.5<\/p><\/td> 4.3<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td><\/tr> Strontium Ranelate<\/p><\/td> 7.0<\/p><\/td> 7.8<\/p><\/td> 9.0<\/p><\/td> 9.2<\/p><\/td> 7.3<\/p><\/td> 0.6<\/p><\/td> 0.6<\/p><\/td> 0.6<\/p><\/td> 0.5<\/p><\/td> 0.2<\/p><\/td><\/tr> Teriparatide<\/p><\/td> 0.3<\/p><\/td> 0.4<\/p><\/td> 0.4<\/p><\/td> 0.5<\/p><\/td> 0.6<\/p><\/td> 2.7<\/p><\/td> 2.8<\/p><\/td> 2.7<\/p><\/td> 3.1<\/p><\/td> 3.2<\/p><\/td><\/tr> Zoledronic Acid<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 16.7<\/p><\/td> 18.0<\/p><\/td> 20.9<\/p><\/td> 23.7<\/p><\/td> 25.7<\/p><\/td><\/tr> Other Calcium Supplement Preps<\/p><\/td> 0.5<\/p><\/td> 0.6<\/p><\/td> 0.6<\/p><\/td> 0.5<\/p><\/td> 0.5<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td><\/tr> Other drugs3<\/sup><\/p><\/td> 0.2<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.2<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.0<\/p><\/td><\/tr> TOTAL<\/p><\/td> 123.8<\/p><\/td> 126.8<\/p><\/td> 123.4<\/p><\/td> 119.1<\/p><\/td> 115.4<\/p><\/td> 39.6<\/p><\/td> 39.6<\/p><\/td> 42.3<\/p><\/td> 46.2<\/p><\/td> 55.0<\/p><\/td><\/tr><\/tbody><\/table> <\/p> 1 <\/sup>Cost of drugs at NHS list price. It does not take account of discounts, dispensing costs, fees or prescription charges income. Totals may not add up due to rounding.<\/p> <\/p> 2<\/sup> The patent for some of these drugs may have expired during this period.<\/p> <\/p> 3<\/sup> \u201cOther drugs\u201d includes Calcium and Colecalciferol and Ergocalciferol, Calcium and Etidronic Acid, Calcium and Risedronic and Colecalciferol, Disodium Pamidronate, Ergocalciferol and Calcium, Etidronic Acid, Hydroxyapatite, Parathyroid Hormone, Salcatonin, Tiludronic Acid, other Bisphosphonate and other Preparations.<\/p> <\/p> <\/p> <\/p> Source: <\/em><\/p> <\/p> Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care)<\/p> <\/p> Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care)<\/p> <\/p> <\/p> <\/p> Since some drugs are prescribed to treat more than one condition and as the condition for which a drug is prescribed is not collected, it is not possible to separate the different conditions for which a drug may have been prescribed. The information provided may therefore include costs from the prescribing of these drugs for conditions other than for osteoporosis.<\/p> <\/p> <\/p> <\/p> <\/p> <\/p> <\/strong><\/p> <\/p> <\/strong><\/p> <\/p> <\/strong><\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-30", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-10-30T16:09:20.4432894Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Osteoporosis: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much has been spent on prescriptions for the treatment of osteoporosis in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester West"}
, "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
], "uin" : "211731"}
, {"_about" : "http://data.parliament.uk/resources/100721", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/100721/answer", "answerText" : {"_value" : " The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p> <\/p> <\/p> <\/p> £ million<\/em><\/p> <\/p> 2009-10<\/p><\/td> 2010-11<\/p><\/td> 2011-12<\/p><\/td> 2012-13<\/p><\/td> 2013-14<\/p><\/td><\/tr> Asthma<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> Other Research Councils and Innovate UK<\/p><\/td> 0.0<\/p><\/td> 0.1<\/p><\/td> 0.3<\/p><\/td> 1.5<\/p><\/td> 0.8<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 2.6<\/p><\/td> 3.4<\/p><\/td> 2.4<\/p><\/td> 3.4<\/p><\/td> 3.8<\/p><\/td><\/tr> Total<\/p><\/td> Motor Neurone Research<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> 7.0<\/p><\/td> 7.5<\/p><\/td> 4.2<\/p><\/td> 4.1<\/p><\/td> 3.6<\/p><\/td><\/tr> Other Research Councils and Innovate UK<\/p><\/td> 0.2<\/p><\/td> 0.2<\/p><\/td> 0.4<\/p><\/td> 0.7<\/p><\/td> 1.0<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.4<\/p><\/td> 0.7<\/p><\/td> 0.5<\/p><\/td><\/tr> Total<\/p><\/td> 7.3<\/p><\/td> 7.8<\/p><\/td> 5.0<\/p><\/td> 5.5<\/p><\/td> 5.1<\/p><\/td><\/tr> Osteoporosis<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> 6.2<\/p><\/td> 5.4<\/p><\/td> 5.1<\/p><\/td> 4.6<\/p><\/td> 5.9<\/p><\/td><\/tr> Other Research Councils and Innovate UK<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.1<\/p><\/td> 0.4<\/p><\/td> 1.0<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 0.3<\/p><\/td> 0.7<\/p><\/td> 0.8<\/p><\/td> 1.3<\/p><\/td> 1.8<\/p><\/td><\/tr> Total<\/p><\/td> 6.5<\/p><\/td> 6.1<\/p><\/td> 6.0<\/p><\/td> 6.3<\/p><\/td> 8.7<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p> <\/p> <\/p> <\/p> Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p> <\/p> <\/p> <\/p> Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100721/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
}
, "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"}
], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Osteoporosis"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much from the publich purse has been spent on research into osteoporosis in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester West"}
, "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
], "uin" : "211732"}
, {"_about" : "http://data.parliament.uk/resources/100722", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/100722/answer", "answerText" : {"_value" : " The National Health Service annual workforce census provides information on the number of nursing, midwifery and health visiting staff employed in the NHS in England but does not separately identify specialist nurses employed in neurological conditions.<\/p> <\/p> <\/p> <\/p> It is for local NHS organisations with their knowledge of the healthcare needs of their local population to invest in training for specialist skills and to deploy specialist nurses. Specialist nurses provide invaluable support for patients and their families. They are able to provide specialist treatment and advice and act as a gateway to other members of the multidisciplinary team, which can both save the NHS money and, more importantly, improve care and outcomes for patients.<\/p> <\/p> <\/p> <\/p> Health Education England (HEE) supports employers with Continuous Personal and Professional Development. HEE's planning process has created the opportunity for employers, through their membership of local education training boards, to prioritise investment between training the future supply of healthcare professional and the development of existing staff, but it is currently for these local partnerships to identify their relative priorities for investment.<\/p> <\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"}
}
, "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"}
, "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"}
, "dateOfAnswer" : {"_value" : "2014-10-30", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-10-30T16:25:48.4053292Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Neurology: Nurses"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how many full-time equivalent specialist nurses for a neurological condition were employed in each region of England in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester West"}
, "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
], "uin" : "211733"}
, {"_about" : "http://data.parliament.uk/resources/100723", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/100723/answer", "answerText" : {"_value" : " The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p> <\/p> <\/p> <\/p> £ million<\/em><\/p> <\/p> 2009-10<\/p><\/td> 2010-11<\/p><\/td> 2011-12<\/p><\/td> 2012-13<\/p><\/td> 2013-14<\/p><\/td><\/tr> Asthma<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> Other Research Councils and Innovate UK<\/p><\/td> 0.0<\/p><\/td> 0.1<\/p><\/td> 0.3<\/p><\/td> 1.5<\/p><\/td> 0.8<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 2.6<\/p><\/td> 3.4<\/p><\/td> 2.4<\/p><\/td> 3.4<\/p><\/td> 3.8<\/p><\/td><\/tr> Total<\/p><\/td> Motor Neurone Research<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> 7.0<\/p><\/td> 7.5<\/p><\/td> 4.2<\/p><\/td> 4.1<\/p><\/td> 3.6<\/p><\/td><\/tr> Other Research Councils and Innovate UK<\/p><\/td> 0.2<\/p><\/td> 0.2<\/p><\/td> 0.4<\/p><\/td> 0.7<\/p><\/td> 1.0<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.4<\/p><\/td> 0.7<\/p><\/td> 0.5<\/p><\/td><\/tr> Total<\/p><\/td> 7.3<\/p><\/td> 7.8<\/p><\/td> 5.0<\/p><\/td> 5.5<\/p><\/td> 5.1<\/p><\/td><\/tr> Osteoporosis<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> 6.2<\/p><\/td> 5.4<\/p><\/td> 5.1<\/p><\/td> 4.6<\/p><\/td> 5.9<\/p><\/td><\/tr> Other Research Councils and Innovate UK<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.1<\/p><\/td> 0.4<\/p><\/td> 1.0<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 0.3<\/p><\/td> 0.7<\/p><\/td> 0.8<\/p><\/td> 1.3<\/p><\/td> 1.8<\/p><\/td><\/tr> Total<\/p><\/td> 6.5<\/p><\/td> 6.1<\/p><\/td> 6.0<\/p><\/td> 6.3<\/p><\/td> 8.7<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p> <\/p> <\/p> <\/p> Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p> <\/p> <\/p> <\/p> Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100723/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
}
, "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"}
], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Motor Neurone Disease: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much from the public purse has been spent on the development of new drugs to prevent or treat symptoms of motore neurone disease in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester West"}
, "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
], "uin" : "211734"}
, {"_about" : "http://data.parliament.uk/resources/100724", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/100724/answer", "answerText" : {"_value" : " Information on National Health Service expenditure on drugs for the treatment of motor neurone disease in primary and secondary care is in the table.<\/p> <\/p> <\/strong><\/p> <\/p> Riluzole is the only drug defined in the British National Formulary as being used for the treatment of motor neurone disease<\/p> <\/p> <\/p> <\/p> Cost of riluzole, England1<\/sup><\/p><\/td><\/tr> Year<\/p><\/td> Primary Care<\/p> (£ million)<\/p><\/td> Secondary Care<\/p> (£ million)<\/p><\/td><\/tr> 2009<\/p><\/td> 3.8<\/p><\/td> 1.2<\/p><\/td><\/tr> 2010<\/p><\/td> 4.9<\/p><\/td> 1.4<\/p><\/td><\/tr> 2011<\/p><\/td> 5.5<\/p><\/td> 1.4<\/p><\/td><\/tr> 2012<\/p><\/td> 5.8<\/p><\/td> 1.5<\/p><\/td><\/tr> 20132<\/sup><\/p><\/td> <\/td> 22.2 <\/del>6.6<\/ins><\/p><\/td>17.5 <\/del>5.3<\/ins><\/p><\/td>17.2<\/del> 4.5<\/ins><\/p><\/td>19.4<\/del> 3.6<\/ins><\/p><\/td>18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>24.8<\/del> 9.2<\/ins><\/p><\/td>21.0<\/del> 8.8<\/ins><\/p><\/td>19.9<\/del> 7.2<\/ins><\/p><\/td>24.3 <\/del>8.5<\/ins><\/p><\/td>23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr> <\/td> 22.2 <\/del>6.6<\/ins><\/p><\/td>17.5 <\/del>5.3<\/ins><\/p><\/td>17.2<\/del> 4.5<\/ins><\/p><\/td>19.4<\/del> 3.6<\/ins><\/p><\/td>18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>24.8<\/del> 9.2<\/ins><\/p><\/td>21.0<\/del> 8.8<\/ins><\/p><\/td>19.9<\/del> 7.2<\/ins><\/p><\/td>24.3 <\/del>8.5<\/ins><\/p><\/td>23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr> <\/td> 22.2 <\/del>6.6<\/ins><\/p><\/td>17.5 <\/del>5.3<\/ins><\/p><\/td>17.2<\/del> 4.5<\/ins><\/p><\/td>19.4<\/del> 3.6<\/ins><\/p><\/td>18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>24.8<\/del> 9.2<\/ins><\/p><\/td>21.0<\/del> 8.8<\/ins><\/p><\/td>19.9<\/del> 7.2<\/ins><\/p><\/td>24.3 <\/del>8.5<\/ins><\/p><\/td>23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr> <\/td> 22.2 <\/del>6.6<\/ins><\/p><\/td>17.5 <\/del>5.3<\/ins><\/p><\/td>17.2<\/del> 4.5<\/ins><\/p><\/td>19.4<\/del> 3.6<\/ins><\/p><\/td>18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>24.8<\/del> 9.2<\/ins><\/p><\/td>21.0<\/del> 8.8<\/ins><\/p><\/td>19.9<\/del> 7.2<\/ins><\/p><\/td>24.3 <\/del>8.5<\/ins><\/p><\/td>23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>